Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook

Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.

The pharmaceutical and medical technology firm posted adjusted earnings per share (EPS) of $2.77 on revenue of $21.89 billion. Analysts had expected $2.56 and $21.56 billion, respectively, according to estimates compiled by Visible Alpha.

Johnson & Johnson shares were up about 1% immediately following the report. They entered the day up about 7% since the start of the year.

The company lifted its projected sales range to $91.0 billion to $91.8 billion, up from $89.2 billion to $90.0 billion previously. It also held its adjusted EPS forecast steady at $10.50 to $10.70, “including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange.”

Since reporting a disappointing 2025 sales outlook in January, the company closed its nearly $15 billion acquisition of Intra-Cellular Therapies and announced plans to lift its U.S. investment to more than $55 billion over the next four years.

Johnson & Johnson stock slipped earlier this month after a judge rejected its proposed “prepackaged bankruptcy plan” for a subsidiary that would settle thousands of claims alleging its talc products caused cancer.